meetings

                  DR. WAGNER:  We want to do in our final session, Roundtable Session today, what we always afford folks.  And those of you that were here this morning saw the drill, so you won't be surprised at the question that begins our conversation.  And that is to run down the table and ask you in your particular areas in the sessions that we had this afternoon on both education and direct‑to‑consumer issues regarding incidental findings, that one thing you would want to be certain that our Commission takes into consideration as we prepare the report.

                        DR. GUTMANN:  Our first speaker is Dr. Thomas Donaldson, the Mark Winkelman Professor of Legal Studies at the Wharton School of the University of Pennsylvania.  Dr. Donaldson is also the director of Zicklin Center for Business Ethics Research at Wharton and his book, "Ties That Bind: A Social Contracts Approach To Business Ethics" was the winner of the 2005 SIM Academy of Management Best book Award.

                        DR. WAGNER:  And welcome everybody back.

                        This panel is assembled like our prior panel, except focusing in the area of ‑‑ in the clinical context.  And again, we're delighted to have three speakers representing three different perspectives here.

                        And our first speaker is Haavi Morreim ‑‑ am I saying that ‑‑ it's good enough?  You know not to challenge me from my prior ‑‑ and she is professor in the department of internal medicine in the College of Medicine at the University of Tennessee.

                        DR. GUTMANN:  We have a tradition now after hearing from each of you individually, we find it's really helpful to have a roundtable so we can discuss among ourselves and hear from each of you advice that you would have for us on the report that we will do.

                        The tradition is to ask each of you, we will go down the line starting with Robert.

                        If there is one specific issue that we address or one specific recommendation or finding that you would advise us to include in our report, what would that be?

                        DR. GUTMANN:  We are going to make a quick transition to our next panel.

                        DR. WAGNER:  Please, Drs. London, Bandettini and Hilgenberg, please come forward.  I said that wrong!  Bandettini.  I apologize.

                        It is my privilege to introduce this next panel to the Commission.  This is the first of the panels that Lisa described to us, where we will be able to hear from an ethicist, a practitioner, and someone whose incidental findings were reflected in some unique way.

                        DR. GUTMANN:  So our first panel this morning, we're going to hear about the ethical challenges of emerging technologies quite generally and how these challenges can inform our understanding and approach to the topic of incidental findings.  We'll hear from each speaker for ten minutes and then we're going to open the session for questions and discussions.  A quick reminder.  When you speak, make sure you've turned your mike on and the red light will come on.  And we will begin with our first speaker, Dr.

(15-minute break) --

DR. GUTMANN:  Good morning, everybody, I'm Amy Gutmann. I’m President of the University of Pennsylvania and Chair of the Presidential Commission for the Study of Bioethical Issues, and I welcome you all here to day two of our 12th meeting of this Commission and happy to do so on behalf of myself and Vice Chair of the Commission and President of Emory University, President Jim Wagner.

DR. GUTMANN:  I’m going to ask our commission members to assemble so we can get started, and welcome everybody back from lunch. 

           We’re going to turn to the ethical considerations associated with pre-event medical countermeasure (MCM) research and such studies -- just to frame -- present no prospect of direct benefit to participants because prior to an event or an imminent event, no children will be affected by the condition that the countermeasure is designed to treat.  And generally, research with children must pose no greater than minimal risk to participants.